Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Xtant Medical Holdings (XTNT) Depreciation & Amortization - Total (2016 - 2019)

Xtant Medical Holdings has reported Depreciation & Amortization - Total over the past 10 years, most recently at $800000.0 for Q3 2019.

  • Quarterly Depreciation & Amortization - Total changed 0.0% to $800000.0 in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $800000.0 through Jun 2020, down 74.19% year-over-year, with the annual reading at $3.2 million for FY2018, 15.79% down from the prior year.
  • Depreciation & Amortization - Total was $800000.0 for Q3 2019 at Xtant Medical Holdings, up from $700000.0 in the prior quarter.
  • Over five years, Depreciation & Amortization - Total peaked at $2.0 million in Q3 2017 and troughed at -$100000.0 in Q4 2017.
  • The 5-year median for Depreciation & Amortization - Total is $747850.0 (2016), against an average of $653061.0.
  • Year-over-year, Depreciation & Amortization - Total plummeted 139.99% in 2017 and then skyrocketed 900.0% in 2018.
  • A 5-year view of Depreciation & Amortization - Total shows it stood at $112750.0 in 2015, then surged by 121.8% to $250078.0 in 2016, then plummeted by 139.99% to -$100000.0 in 2017, then skyrocketed by 900.0% to $800000.0 in 2018, then changed by 0.0% to $800000.0 in 2019.
  • Per Business Quant, the three most recent readings for XTNT's Depreciation & Amortization - Total are $800000.0 (Q3 2019), $700000.0 (Q2 2019), and $800000.0 (Q1 2019).